Immutep's Autoimmune Drug IMP761 Completes Phase I SAD with Positive Safety, Immunosuppressive Effect
Summary
Immutep announced positive progress from the single ascending dose (SAD) portion of its Phase I study for IMP761, a LAG-3 agonist targeting autoimmune diseases. The drug was well tolerated across all dose levels, with no safety concerns or dose-limiting toxicities observed, and demonstrated a clear immunosuppressive effect. This early positive clinical update for IMP761 in autoimmune diseases provides a notable development for Immutep, especially following the recent halting of its Phase III TACTI-004 study for a cancer drug due to futility. While still in early stages, this progress offers a potential new pipeline path and diversification for the company. Investors will now watch for the completion of the multiple ascending dose (MAD) portion, expected in Q3 2026, and further data presentation at the EULAR congress on June 4, 2026.
At the time of this announcement, IMMP was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.9M. The 52-week trading range was $0.40 to $3.53. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.